We are live on !
Find out more
SCM
Superstring Capital Management Portfolio holdings
AUM
$158M
Turnover
44.19%
1-Year Est. Return
418.32%
This Fund
S&P 500
This Quarter Est. Return
+40.72%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$158M
AUM Growth
+$18.4M
(+13%)
Cap. Flow
-$14.8M
Cap. Flow % of AUM
Cap. Flow %
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
63.75%
Holding
43
New
8
Increased
13
Reduced
9
Closed
11
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$9.26M |
| 2 |
Revolution Medicines
RVMD
|
+$7.46M |
| 3 |
Genmab
GMAB
|
+$6.22M |
| 4 |
Cogent Biosciences
COGT
|
+$4.13M |
| 5 |
Trevi Therapeutics
TRVI
|
+$3.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Summit Therapeutics
SMMT
|
+$16.9M |
| 2 |
UroGen Pharma
URGN
|
+$5.31M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$4.92M |
| 4 |
Immunovant
IMVT
|
+$4.55M |
| 5 |
IQVIA
IQV
|
+$4.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cogent Biosciences
COGT
$5.21B
| $13.3M | 8.39% |
343,284
+118,126
| +52% | +$4.13M |
2024 Q4
6 quarters
|
|
|
2
Axsome Therapeutics
AXSM
$8.16B
| $13.2M | 8.33% |
53,916
+42,699
| +381% | +$9.26M |
2025 Q4
2 quarters
|
|
|
3
Genmab
GMAB
$23.7B
| $11.8M | 7.47% |
430,600
+233,891
| +119% | +$6.22M |
2025 Q4
2 quarters
|
|
4
Celldex Therapeutics
CLDX
$2.33B
| $10.7M | 6.76% |
287,583
+107,535
| +60% | +$3.47M |
2025 Q4
2 quarters
|
|
|
5
Trevi Therapeutics
TRVI
$1.7B
| $9.8M | 6.17% |
524,224
+272,658
| +108% | +$3.97M |
2025 Q4
2 quarters
|
|
|
6
Revolution Medicines
RVMD
$39B
| $9.6M | 6.04% |
+51,053
| New | +$7.46M |
2026 Q2
0 quarters
|
|
7
Definium Therapeutics
DFTX
$4.43B
| $8.86M | 5.59% |
188,282
-163,179
| -46% | -$4.03M |
2025 Q4
2 quarters
|
|
8
Vir Biotechnology
VIR
$1.73B
| $8.7M | 5.49% |
853,685
+123,137
| +17% | +$1.17M |
2026 Q1
1 quarter
|
|
|
9
Immunovant
IMVT
$5.7B
| $8.03M | 5.07% |
208,368
-149,238
| -42% | -$4.55M |
2025 Q3
3 quarters
|
|
|
10
UroGen Pharma
URGN
$1.67B
| $7.04M | 4.45% |
191,313
-196,058
| -51% | -$5.31M |
2024 Q4
6 quarters
|
|
11
Climb Bio
CLYM
$559M
| $6.79M | 4.29% |
521,082
+321,873
| +162% | +$3.32M |
2026 Q1
1 quarter
|
|
12
Adlai Nortye Group ADS
ANL
$668M
| $6.35M | 4.01% |
552,501
+137,649
| +33% | +$1.67M |
2026 Q1
1 quarter
|
|
13
Savara
SVRA
$951M
| $6.02M | 3.8% |
977,460
-608,517
| -38% | -$3.27M |
2023 Q4
10 quarters
|
|
14
MapLight Therapeutics
MPLT
$445M
| $4.5M | 2.84% |
125,432
-66,707
| -35% | -$1.92M |
2026 Q1
1 quarter
|
|
15
Oric Pharmaceuticals
ORIC
$1.32B
| $4.4M | 2.78% |
406,077
+290,843
| +252% | +$2.64M |
2024 Q3
7 quarters
|
|
16
United Therapeutics
UTHR
$23.3B
| $3.89M | 2.45% |
7,172
+1,986
| +38% | +$1.12M |
2025 Q4
2 quarters
|
|
17
Vaxcyte
PCVX
$10B
| $3.88M | 2.45% |
66,793
-43,661
| -40% | -$2.37M |
2026 Q1
1 quarter
|
|
18
BeOne Medicines Ltd
ONC
$41.9B
| $3.5M | 2.21% |
+12,273
| New | +$3.62M |
2026 Q2
0 quarters
|
|
19
Cabaletta Bio
CABA
$251M
| $3.48M | 2.2% |
1,278,652
+212,413
| +20% | +$699K |
2024 Q1
9 quarters
|
|
20
Zai Lab
ZLAB
$2.7B
| $2.96M | 1.87% |
155,813
-120,005
| -44% | -$2.37M |
2024 Q2
8 quarters
|
|
21
Sionna Therapeutics
SION
$181M
| $2.78M | 1.75% |
63,156
-77,868
| -55% | -$3.11M |
2025 Q4
2 quarters
|
|
22
Bright Minds Biosciences
DRUG
$531M
| $2.14M | 1.35% |
30,456
+17,145
| +129% | +$1.35M |
2025 Q3
3 quarters
|
|
23
Aclaris Therapeutics
ACRS
$512M
| $1.36M | 0.86% |
257,675
-108,815
| -30% | -$485K |
2026 Q1
1 quarter
|
|
|
HELP
24
Helus Pharma Inc. Common Stock
HELP
$781M
| $1.35M | 0.85% |
+204,424
| New | +$1.02M |
2026 Q2
0 quarters
|
|
25
Kiniksa Pharmaceuticals
KNSA
$6.2B
| $1.21M | 0.76% |
+18,867
| New | +$979K |
2026 Q2
0 quarters
|
|
Similar funds
FCM
SF
CCA
VFIA
SWM
AWA
MA
BA
Superstring Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Superstring Capital Management held 43 positions worth $158M, up 13% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Superstring Capital Management withdrew a net $14.8M in Q2 2026, closing 11 positions and reducing 9 holdings. Its most notable exit was Summit Therapeutics, an estimated $16.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Superstring Capital Management opened a new position in Revolution Medicines worth $9.6M.
- Superstring Capital Management's largest Q2 2026 buy was Revolution Medicines: 51,053 shares worth $9.6M.
- Superstring Capital Management added most to Axsome Therapeutics in Q2 2026, an estimated $9.26M increase.
- Superstring Capital Management's biggest Q2 2026 reduction was UroGen Pharma, cutting an estimated $5.31M.
- Superstring Capital Management fully exited Summit Therapeutics in Q2 2026, selling an estimated $16.9M.
- Superstring Capital Management's ten largest holdings make up 64% of its $158M portfolio in Q2 2026.
- Superstring Capital Management opened 8 new positions and closed 11 in Q2 2026.
- Superstring Capital Management's portfolio value rose 13% quarter-over-quarter to $158M.
Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.